apo{a) was expressed in transgenic mice such that it was minimally
incorporated into lipoprotein particles, early development of athero-
sclerotic lesions was observed (59). Thus, properties af Lp(a) depen-
dent upon the apo(a) moiety, such as its interaction with plasminogen
binding sites on cells, may contribute to its pathogenetic effects.

Acknowledgements

We wish to thank Denise Hickey for excellent technical assistance and
Shari Olsen for excellent secretarial assistance. This work was supported in
part by NIH grants HL (8577, HL 43344, HL 35297, HL 38272, HL-45934,
HL 14197, and MO] RR 00833 to the GCRC of Scripps Clinic. This work was
done during the tenure of Established Investigatorship awards from the Ameri-
can Heart Association and SmithKline Beecham to L. A. M. and from the
American Heart Association to E. G. L.

References

1. Dahlén GH, Berg K, Gillnas T, Ericson C. Lp(a) lipoprotein/pre-B1-lipo-
protein in Swedish middle-aged males and in patients with coronary heart
disease. J Clin Genet 1975; 7; 334-41.

2. Koltringer P, Jurgens G. A dominant rule of lipoprotein(a) in the investiga-
ton and evaluation of parameters indicating the development of cervical
atherosclerosis, Atherosclerosis 1985; 58: 187-98.

3. Rhodes GG, Dahlén CrH, Berg K, Morton NE, Dannenberg AL. Lp(a)
lipoprotein as a risk factor for myocardial infarction. JAMA 1986; 256:
2540-4.

4, Hoefler G, Harnoncourt F, Paschke E, Mirti W, Pfeiffer KH, Kostner GM.
Lipoprotein Lp(a). A risk factor for myocardial infarction. Arteriosclerosis
1988; 8: 398-401.

5. Moliterno DJ, Lange RA, Meidell RS, Willard JE, Leffert CC, Gerard RD,
Boerwinkle E, Hobbs HH, Hillis LD. Relation of plasma lipoprotein(a) to
infarct artery patency in survivors of myocardial infarction. Circulation
1993; 88: 935-40,

6. Howard GC, Pizza SV. Biology of disease: Lipoprotein(a) and its role in
atherothrombotic disease. Lab Invest 1993; 69: 373-86.

7, Scanu AM. Stroctural basis for the presumptive atherotirombogenic action
of lipoprotein(a). Facts and speculations. Biochem Pharmacol 1993; 46:
1675-80.

8. McLean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen EY, Fless GM,
Scanu AM, Lawn RM. cDNA sequence of human apolipoprolein(a) is
homologous to plasminogen. Nature 1987; 330: 132-7,

“9. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of tipopro-
tein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989;
86; 3847-51.

10. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin
binding, and plasminogen activation. Anteriosclerasis 1990; 10: 240-5.

iL. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein{a) inhibition of
plasminogen activation by tissue-type plasminogen activator. Thromb Res
1990; 57: 155-62.

12. Karadi I, Kostner GM, Gries A, Nimpf J, Romics L, Malle E. Lipopro-
tein(a) and plasminogen are immunochemically related. Biochirn Biophys
Acta 1988; 960: 91-7.

13. Edetberg JM, Gonzalez-Gronow M, Pizzo SV, Lipoprotein a inhibits strep-
tokinase-mediated activation of human plasminogen. Biochemistry 1989;
28: 2370-4. .

14. Kluft C, Jie AFH, Los P, de Wit E, Havekes L. Functional analogy between
hpoprotein(a) and plasminogen in the binding to the kringle 4 binding pro-
tein, tetranectin. Biochem Biophys Res Commun 1989; 161'427-33,

15. Rouy D, Grailhe P. Nigon F, Chapman J, Anglés-Cano E. Lipoprotein(a)
impairs generation of plasmin by fibrin-bound tissue-type plusminogen
activator: In vitro studies in a plasma milieu. Arteriosclerasis 1991; 11:
629-38

aed

 

“40005205

16. Miles LA, Dalilberg CM, Plow EF. The cell-binding domains of plasmino-
gcn and their function in plasma. J Bio Chem 1.988; 263: 11928-34.

17. Gonzalez-Gronow M, Edetherg JM, Pizzo, SV. Further characterization
of the cellular plasminogen binding site: Evidence that plasminogen 2
and lipoproteinfa} compete for the same site, Biochemistry 1989; 28:
2374-7.

18. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis
for the thrombotic risks associated with Jipoprotein{a). Nature 1989;
339: 301-3.

19. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modula-
tion of endothelial cell surface fibrinolysis and its potential role in athero-
sclerosis. Nature 1989; 339: 303-5.

20, Ezratty A, Simon DI, Loscalzo J. Lipoprotein(a) binds to human platelets
and attenuates plasminogen binding and activation. Biochemistry 1993; 32:
4628-33.

21. Snyder ML, Polacek D, Scanu AM, Fless GM. Comparative binding and
degradation of lipoprotein(a) and low density lipoprotein by human mono-
cyte derived macrophages. J Biol Chem 1992; 267: 339-46.

22. Kostner GM, Grillhofer HK. Lipoprotein(a) mediates high affinity low den-
sily lipoprotein association to receptor negative fibroblasts. J Biol Chem
1991; 266: 21287-92.

23. Ziencheck TF, Powell LM, Rice GC, Eaton DL, Lawn RM. Interaction of
recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J Clin
Envest. 1991; 87: 767-71.

24. Havekes L, Vermeer BJ, Brugman T, Emeis J. Binding of Lp(a) to the low
density lipoprotein receptor of human fibroblasts. FEBS Lett! 981; 132:
169-73.

. Armstrong V, Harrach B, Robenek H, Helmbold M, Walli AK, Seidel B.
Heterogeneity of human lipoprotein Lpfa]: cytochemical and biochemical
studies on the interaction of two Lp[a] species with the LDL receptor.
J Lipid Res 1990; 31: 429-41.

26. Hofmann SL, Eaton DL, Brown MS, McConathy WJ, Goldstein JL, Ham-
mer RE, Overexpression of human low density lipoprotein receptors leads
to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin
Invest 1990; 85: 1542-7, :

27, Haberland ME, Fless G, Scanu AM, Fogetman AM. Modification of Lpfaj
by malondialdehyde leads to avid uptake by human monocyte-macro-
phages. Circulation 1989; 80, Suppl II: 163.

28, Miller NE. Induction of low density lipoprotein receptor synthesis by high
density lipoprotein in cultures of human skin fibroblasts. Biochim Biophys
Acta 1978; 529: 131-7.

29. Curtiss LK, Plow EF. Interaction of plasma lipoproteins with human plate-
lets. Blood 1984; 64: 365-74. -

30, Alexander JJ, Remedios M, Graham D. High density lipoprotein inhibits
low density lipoprotein binding and uptake by bovine aortic endothelial
cells. Angiclogy 1990; 41: 1065-9.

31. Virgolini I, Li $, Qiong Y, Banyai M, Koller E, Angelberger P, Sinzinger
H. Binding of 'In-labeled HDL to platelets from normolipemic volunteers
and patients with heterozygous familial hypercholesterolemia. Arterioscler.
Thromb 1992; 12: 849-61.

32. Fless GM, Rolih CA, Scanu AM. Heterogeneity of human plasma lipopro-
tein(a) Isolation and characterization of the lipoprotein subspecies and their
apoproteins. J Biol Chem 1984; 259: 11470-8.

33. Laton DL, Fless GM, Kohr WJ, McLean IW, Xu QT, Miller, CG, Lawn
RM, Scanu AM. Partial amino acid sequence of apolipopratein(a) shows
that it is homologous to plasminogen, Proc Natl Acad Sci USA 1987; 84:
3224-8.

34. Curtiss LK, Edgington TS, Immunochemical heterogeneity of human
plasma high densily lipoproteins. J Biol Chem 1985; 260: 2982-93.

35. Basu SK, Brown MS, Ho YK, Havel RJ, Goldstein JL. Mouse macrophages
synthesize and secrete a protein resembling apolipoprotein E. Proc Natl
Acad Sci USA 1981, 78: 7545-9.

36. Markwell MAK, Haas SM, Bieber LL, Tolbert NE, A modification of the
Lowry procedure to simplify protein determination in membrane and lipo-
protein samples. Anal Biochem 1978; 87: 206-10.

Ww
La